GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (LTS:0RA9) » Definitions » Valuation Rank

Abivax (LTS:0RA9) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is Abivax Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Abivax Valuation Rank Related Terms

Thank you for viewing the detailed overview of Abivax's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (LTS:0RA9) » Definitions » Valuation Rank
Comparable Companies
XPAR:MEDCL XPAR:VLA XPAR:ALSEN XPAR:GNFT XPAR:IPH XPAR:OSE XPAR:ALCLS XPAR:NANO XPAR:IVA XPAR:MAAT VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
ABVX:USA ABVX:France 2X10:Germany 2X1:Germany 2X1:Germany
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Website
https://www.abivax.com
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.